Allergan fell$. 61 or. 3 percent, to $234.80. Baxter International Inc. fell$. 83 or 1.2 percent, to $68.38. Boston Scientific Corp. fell$. 26 or 1.5 percent, to $16.71.» Read More
Lawrence Livermore is reaching out to private industry amid a race for talent and ideas to solve pressing issues including national security.
CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
As healthcare reform begins to take shape, venture capitalists see emerging opportunities in digital health start-ups.
P&G is bringing the dentist into your bathroom a smartphone-connected toothbrush, a device that gives personalized advice to help people improve their brushing.
The White House is coming under pressure from some of its closest allies to name a CEO to run its health insurance marketplace.
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
An entrepreneur has attracted investments from four billionaires: Sam Zell, Herb Simon, David Bonderman and "one family you've never heard of."
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
Like all computers, Intuitive Surgical's da Vinci robot can malfunction during surgery. A range of results have been reported by surgeons.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.